RecruitingPhase 3NCT05035030
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
Studying Alagille syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Albireo, an Ipsen Company
- Principal Investigator
- Ipsen Medical DirectorIpsen
- Intervention
- Odevixibat(drug)
- Enrollment
- 70 enrolled
- Eligibility
- All sexes
- Timeline
- 2021 – 2026
Study locations (20)
- Rady Children's Hospital, San Diego, California, United States
- UCSF, San Francisco, California, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Children's Mercy Hospital and Clinics, Kansas City, Missouri, United States
- Northwell Health System, New Hyde Park, New York, United States
- Hassenfeld Children's Hospital at NYU Langone, New York, New York, United States
- The Childrens Hospital at Montefiore Albert Einstein School of Medicine, The Bronx, New York, United States
- Atrium Health Carolinas Medical, Durham, North Carolina, United States
- Cincinnati Children's Hospital, Cincinnati, Ohio, United States
- Oregon Health Science University School of Medicine, Portland, Oregon, United States
- Monroe Carell Jr. Childrens Hospital at Vanderbilt, Nashville, Tennessee, United States
- Childrens Medical Center of Dallas University of Texas Southwestern, Dallas, Texas, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05035030 on ClinicalTrials.govOther trials for Alagille syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07411716Pediatric Evaluation and Registry for Liver Cholestasis in CanadaChildren's Hospital of Eastern Ontario
- RECRUITINGNCT07293897A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)Takeda
- RECRUITINGPHASE4NCT07290257Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)Mirum Pharmaceuticals, Inc.
- RECRUITINGNCT06850038A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing TreatmentIpsen
- RECRUITINGNCT06193928Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)Mirum Pharmaceuticals, Inc.